BPI-361175

DRUG2 trials

Sponsors

Betta Pharmaceuticals Co., Ltd., Xcovery Holdings, Inc.

Conditions

Non-small Cell Lung CancerNon-small Cell Lung Carcinoma

Phase 1

A Phase 1/2 Study of BPI-361175 in Subjects With Advanced Solid Tumors

Betta Pharmaceuticals Co., Ltd.Non-small Cell Lung Cancer

Start: 2021-07-21End: 2023-12-31Target: 90Updated: 2022-04-15

BPI-361175 Tablets in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Not yet recruitingNCT05393466

Xcovery Holdings, Inc.Non-small Cell Lung Carcinoma

Start: 2026-07-01End: 2029-05-31Target: 30Updated: 2025-10-07